Clinical trial · Interventional
Combination Chemotherapy in Treating Older Patients With Solid Tumour,
Study of a Scale Predicting the Feasibility of Chemotherapy in Patients Aged 75 Years or Older With Solid Tumour
NCT00664911CI-TRIAL-00012402OLDcompletedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This clinical trial is studying how well combination chemotherapy works in treating older patients with solid tumour.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumor Regardless of Localization and Stage | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| chemotherapy | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Chemotherapy
- description
- chemotherapy regimen
- interventionNames
- Other: chemotherapy
Primary outcomes (2)
- measure
- chemotherapy feasibility
- timeFrame
- from inclusion to 3 months
- description
- ability to deliver at least 3 months of the planned regimen therapy.
- measure
- Number of patients receiving therapeutic dose-intensive therapy (doses must be at least equivalent to two-thirds the dose that is usually administered according to AMM recommendations)
- timeFrame
- 3 months
- description
- dose reduction \< 33%
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 75 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed solid tumour regardless of localization or stage PATIENT CHARACTERISTICS: * \> or = 75 years * patient planned to receive \> or = 2/3 of standard dose of the first cycle PRIOR CONCURRENT THERAPY: Chemonaive patient.
References
Publications (0)
Data not yet available
No reference posted for this study.